Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
Privacy Policy
|
|
-
-
Antidepressant induced
cholestasis: hepatocellular redistribution of multidrug resistant
protein (MRP2).
Milkiewicz P, Chilton AP, Hubscher
SG, Elias E.
Liver and Hepatobiliary Unit, Queen Elizabeth
Hospital, Birmingham, UK.
BACKGROUND: We report two cases of
antidepressant induced cholestasis. Case reports: We describe the first
reported case of acute cholestasis due to citalopram (selective
serotonin reuptake inhibitor) occurring in a patient who also
experienced obstetric cholestasis in association with each of three
pregnancies; in a second patient cholestasis developed due to dothiepin
(tricyclic antidepressant), and six years later due to paroxetine. In
both cases liver biopsies showed features of a "pure" cholestasis with
total resolution within 1-6 months after withdrawal of the causative
drug. Immunostaining for the canalicular transporter, multidrug
resistant protein 2 (MRP2), responsible for biliary secretion of several
organic anions including bilirubin glucuronides, showed sustained
expression in both biopsies as well as relocalisation with appearance of
strong staining of the basolateral membrane of the hepatocyte. This
finding has also not been reported previously. CONCLUSIONS: We postulate
that intracellular redistribution of MRP2 may reflect an adaptive
compensatory mechanism which helps in the elimination of the drug or its
cholestatic metabolites from the hepatocyte back to the sinusoidal space
and subsequent excretion in urine. Changes seen in these two patients
differ from findings previously reported in rats where downregulation of
mrp2 occurs in response to experimentally induced cholestasis. We
speculate that the rat is more advanced than humans in its ability to
downregulate canalicular transporter expression as protection against
progressive intrahepatic cholestasis.
Publication Types:
PMID: 12524417 [PubMed - indexed for
MEDLINE]
|